Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
The new functionality complements Parse’s existing Evercode immune products
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
Subscribe To Our Newsletter & Stay Updated
